31 – 40 of 95
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
(
- Contribution to journal › Article
-
Mark
A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung
(
- Contribution to journal › Article
-
Mark
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma
(
- Contribution to journal › Article
-
Mark
A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma
(
- Contribution to journal › Article
-
Mark
Immunomodulation—A Molecular Solution to Treating Patients with Severe Bladder Pain Syndrome?
(
- Contribution to journal › Article
-
Mark
Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
(
- Contribution to journal › Article
-
Mark
Local Destruction of Tumors and Systemic Immune Effects
(
- Contribution to journal › Scientific review
- 2020
-
Mark
ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma
(
- Contribution to journal › Article
-
Mark
Granzyme B degraded type IV collagen products in serum identify melanoma patients responding to immune checkpoint blockade
(
- Contribution to journal › Article